Tumour response prediction by diffusion-weighted MR imaging: Ready for clinical use?

Critical Reviews in Oncology/Hematology

Volumn 83, Issue 2, 2012, Pages 194-207

  Heijmen, Linda ^a   Verstappen, Maartje C H M ^a   ter Voert, Edwin E G W ^a   Punt, Cornelis J A ^b   Oyen, Wim J G ^a   de Geus Oei, Lioe Fee ^a   Hermans, John J ^a   Heerschap, Arend ^a   van Laarhoven, Hanneke W M ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

DCE MRI; Diffusion weighted imaging (DWI); Response monitoring; Response prediction

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVANCED CANCER; APPARENT DIFFUSION COEFFICIENT; BENIGN TUMOR; BRAIN TUMOR; BREAST CANCER; CANCER PROGNOSIS; CANCER SIZE; CANCER THERAPY; CHEMORADIOTHERAPY; CLINICAL EXAMINATION; CONSTANTS AND COEFFICIENTS; DIFFERENTIAL DIAGNOSIS; DIFFUSION WEIGHTED IMAGING; ENDOMETRIUM CANCER; FUNCTIONAL ASSESSMENT; HEAD AND NECK CARCINOMA; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; LIVER METASTASIS; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVARY CANCER; PATIENT MONITORING; PREDICTION; RECTUM CANCER; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; TISSUE EXAMINATION; TREATMENT RESPONSE; VALIDATION PROCESS;

ANIMALS; DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; NEOPLASMS; PROGNOSIS; TREATMENT OUTCOME;

EID: 84864054974     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2011.12.008     Document Type: Review

References (74)

1. Padhani A.R. MRI for assessing antivascular cancer treatments. Br J Radiol 2003, 76(1):S60-S80.
2. Padhani A.R., Leach M.O. Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging. Abdom Imaging 2005, 30:324-341.
3. Cheng H.L., Haider M.A., ll-Macky M.J., Sweet J.M., Trachtenberg J., Gertner M.R. MRI and contrast-enhanced ultrasound monitoring of prostate microwave focal thermal therapy: an in vivo canine study. J Magn Reson Imaging 2008, 28:136-143.
4. Jordan B.F., Runquist M., Raghunand N., et al. Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478. Neoplasia 2005, 7:475-485.
5. Thoeny H.C., De K.F., Vandecaveye V., et al. Effect of vascular targeting agent in rat tumor model: dynamic contrast-enhanced versus diffusion-weighted MR imaging. Radiology 2005, 237:492-499.
6. Vogel-Claussen J., Gimi B., Artemov D., Bhujwalla Z.M. Diffusion-weighted and macromolecular contrast enhanced MRI of tumor response to antivascular therapy with ZD6126. Cancer Biol Ther 2007, 6:1469-1475.
7. Stejskal E.O., Tanner J. Spin diffusion measurements: spinechoes in the presence of a time-dependent field gradient. J Chem Phys 1965, 42:288-292.
8. Progress in diffusion-weighted imaging: concepts, techniques, and applications to the central nervous system. NMR Biomed 2010, 23(7):659-904. Special Issue.
9. Koh D.M., Collins D.J. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR (Am J Roentgenol) 2007, 188:1622-1635.
10. Padhani A.R., Liu G., Mu-Koh D., et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009, 11:102-125.
11. Bammer R., Holdsworth S.J., Veldhuis W.B., Skare S.T. New methods in diffusion-weighted and diffusion tensor imaging. Magn Reson Imaging Clin N Am 2009, 17:175-204.
12. Hagmann P., Jonasson L., Maeder P., Thiran J.P., Wedeen V.J., Meuli R. Understanding diffusion MR imaging techniques: from scalar diffusion-weighted imaging to diffusion tensor imaging and beyond. Radiographics 2006, 26(Suppl. 1):S205-S223.
13. Kuroki Y., Nasu K., Kuroki S., et al. Diffusion-weighted imaging of breast cancer with the sensitivity encoding technique: analysis of the apparent diffusion coefficient value. Magn Reson Med Sci 2004, 3:79-85.
14. Marini C., Iacconi C., Giannelli M., Cilotti A., Moretti M., Bartolozzi C. Quantitative diffusion-weighted MR imaging in the differential diagnosis of breast lesion. Eur Radiol 2007, 17:2646-2655.
15. Partridge S.C., Demartini W.B., Kurland B.F., Eby P.R., White S.W., Lehman C.D. Differential diagnosis of mammographically and clinically occult breast lesions on diffusion-weighted MRI. J Magn Reson Imaging 2010, 31:562-570.
16. Rubesova E., Grell A.S., De M., Metens V., Chao T., Lemort S.L.M. Quantitative diffusion imaging in breast cancer: a clinical prospective study. J Magn Reson Imaging 2006, 24:319-324.
17. Nakajo M., Kajiya Y., Kaneko T., et al. FDG PET/CT and diffusion-weighted imaging for breast cancer: prognostic value of maximum standardized uptake values and apparent diffusion coefficient values of the primary lesion. Eur J Nucl Med Mol 2010, 37:2011-2020.
18. Costantini M., Belli P., Rinaldi P., et al. Diffusion-weighted imaging in breast cancer: relationship between apparent diffusion coefficient and tumour aggressiveness. Clin Radiol 2010, 65:1005-1012.
19. Takeuchi M., Matsuzaki K., Nishitani H. Diffusion-weighted magnetic resonance imaging of endometrial cancer: differentiation from benign endometrial lesions and preoperative assessment of myometrial invasion. Acta Radiol 2009, 50:947-953.
20. Takeuchi M., Matsuzaki K., Nishitani H. Diffusion-weighted magnetic resonance imaging of ovarian tumors: differentiation of benign and malignant solid components of ovarian masses. J Comput Assist Tomogr 2010, 34:173-176.
21. Woodfield C.A., Tung G.A., Grand D.J., Pezzullo J.A., Machan J.T., Renzulli J.F. Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy. AJR (Am J Roentgenol) 2010, 194:W316-W322.
22. Hambrock T., Somford D.M., Huisman H.J., et al. Relationship between apparent diffusion coefficients at 3.0-T MR Imaging and gleason grade in peripheral zone prostate cancer. Radiology 2011, 259:453-461.
23. Nasu K., Kuroki Y., Tsukamoto T., Nakajima H., Mori K., Minami M. Diffusion-weighted imaging of surgically resected hepatocellular carcinoma: imaging characteristics and relationship among signal intensity, apparent diffusion coefficient, and histopathologic grade. AJR (Am J Roentgenol) 2009, 193:438-444.
24. Bacci G., Ferrari S., Bertoni F., et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol 2000, 18:4016-4027.
25. Bielack S.S., Kempf-Bielack B., Delling G., et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002, 20:776-790.
26. Uhl M., Saueressig U., van B.M., et al. Osteosarcoma: preliminary results of in vivo assessment of tumor necrosis after chemotherapy with diffusion- and perfusion-weighted magnetic resonance imaging. Invest Radiol 2006, 41:618-623.
27. Hayashida Y., Yakushiji T., Awai K., et al. Monitoring therapeutic responses of primary bone tumors by diffusion-weighted image: initial results. Eur Radiol 2006, 16:2637-2643.
28. Kamel I.R., Bluemke D.A., Ramsey D., et al. Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. AJR (Am J Roentgenol) 2003, 181:708-710.
29. Guo A.C., Cummings T.J., Dash R.C., Provenzale J.M. Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. Radiology 2002, 224:177-183.
30. Kallehauge J.F., Tanderup K., Haack S., et al. Apparent diffusion coefficient (ADC) as a quantitative parameter in diffusion weighted MR imaging in gynecologic cancer: dependence on b-values used. Acta Oncol 2010, 49:1017-1022.
31. Peters N.H., Vincken K.L., van den Bosch M.A., Luijten P.R., Mali W.P., Bartels L.W. Quantitative diffusion weighted imaging for differentiation of benign and malignant breast lesions: the influence of the choice of b-values. J Magn Reson Imaging 2010, 31:1100-1105.
32. Lyng H., Haraldseth O., Rofstad E.K. Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging. Magn Reson Med 2000, 43:828-836.
33. Mishra A.M., Gupta R.K., Saksena S., et al. Biological correlates of diffusivity in brain abscess. Magn Reson Med 2005, 54:878-885.
34. Rockwell S., Dobrucki I.T., Kim E.Y., Marrison S.T., Vu V.T. Hypoxia and radiation therapy: past history, ongoing research, and future promise. Curr Mol Med 2009, 9:442-458.
35. Vaupel P., Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007, 26:225-239.
36. Dzik-Jurasz A., Domenig C., George M., et al. Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 2002, 360:307-308.
37. Koh D.M., Scurr E., Collins D., et al. Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients. AJR (Am J Roentgenol) 2007, 188:1001-1008.
38. Cui Y., Zhang X.P., Sun Y.S., Tang L., Shen L. Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology 2008, 248:894-900.
39. Mardor Y., Roth Y., Ochershvilli A., et al. Pretreatment prediction of brain tumors' response to radiation therapy using high b-value diffusion-weighted MRI. Neoplasia 2004, 6:136-142.
40. DeVries A.F., Kremser C., Hein P.A., et al. Tumor microcirculation and diffusion predict therapy outcome for primary rectal carcinoma. Int J Radiat Oncol Biol Phys 2003, 56:958-965.
41. Harry V.N., Semple S.I., Gilbert F.J., Parkin D.E. Diffusion-weighted magnetic resonance imaging in the early detection of response to chemoradiation in cervical cancer. Gynecol Oncol 2008, 111:213-220.
42. Nilsen L., Fangberget A., Geier O., Olsen D.R., Seierstad T. Diffusion-weighted magnetic resonance imaging for pretreatment prediction and monitoring of treatment response of patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. Acta Oncol 2010, 49:354-360.
43. Kim S.H., Lee J.M., Hong S.H., et al. Locally advanced rectal cancer: added value of diffusion-weighted MR imaging in the evaluation of tumor response to neoadjuvant chemo- and radiation therapy. Radiology 2009, 253:116-125.
44. Tomura N., Narita K., Izumi J., et al. Diffusion changes in a tumor and peritumoral tissue after stereotactic irradiation for brain tumors: possible prediction of treatment response. J Comput Assist Tomogr 2006, 30:496-500.
45. Okuma T., Matsuoka T., Yamamoto A., Hamamoto S., Nakamura K., Inoue Y. Assessment of early treatment response after CT-guided radiofrequency ablation of unresectable lung tumours by diffusion-weighted MRI: a pilot study. Br J Radiol 2009, 82:989-994.
46. Song I., Kim C.K., Park B.K., Park W. Assessment of response to radiotherapy for prostate cancer: value of diffusion-weighted MRI at 3T. AJR (Am J Roentgenol) 2010, 194:W477-W482.
47. Hein P.A., Kremser C., Judmaier W., et al. Diffusion-weighted magnetic resonance imaging for monitoring diffusion changes in rectal carcinoma during combined, preoperative chemoradiation: preliminary results of a prospective study. Eur J Radiol 2003, 45:214-222.
48. Kim S.H., Lee J.Y., Lee J.M., Han J.K., Choi B.I. Apparent diffusion coefficient for evaluating tumour response to neoadjuvant chemoradiation therapy for locally advanced rectal cancer. Eur Radiol 2011, 21:987-995.
49. Warach S., Chien D., Li W., Ronthal M., Edelman R.R. Fast magnetic resonance diffusion-weighted imaging of acute human stroke. Neurology 1992, 42:1717-1723.
50. Warach S., Gaa J., Siewert B., Wielopolski P., Edelman R.R. Acute human stroke studied by whole brain echo planar diffusion-weighted magnetic resonance imaging. Ann Neurol 1995, 37:231-241.
51. Desar I.M., van Laarhoven H.W., Hambrok T., et al. Assessment of early vascular effects of the angiogenesis inhibitor sunitinib (SU) in renal cell carcinoma (RCC) by dynamic contrast enhanced MRI (DCE-MRI) and diffusion weight MRI (DWI) at 3tesla (T). ASCO 2010.
52. Pickles M.D., Gibbs P., Lowry M., Turnbull L.W. Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging 2006, 24:843-847.
53. Theilmann R.J., Borders R., Trouard T.P., et al. Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia 2004, 6:831-837.
54. Mardor Y., Pfeffer R., Spiegelmann R., et al. Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging. J Clin Oncol 2003, 21:1094-1100.
55. Hamstra D.A., Chenevert T.L., Moffat B.A., et al. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci USA 2005, 102:16759-16764.
56. Moffat B.A., Chenevert T.L., Lawrence T.S., et al. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci USA 2005, 102:5524-5529.
57. Hamstra D.A., Galban C.J., Meyer C.R., et al. Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol 2008, 26:3387-3394.
58. Vandecaveye V., Dirix P., De K.F., et al. Predictive value of diffusion-weighted magnetic resonance imaging during chemoradiotherapy for head and neck squamous cell carcinoma. Eur Radiol 2010, 20:1703-1714.
59. Hylton N. Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol 2006, 24:3293-3298.
60. van Laarhoven H.W., Klomp D.W., Rijpkema M., et al. Prediction of chemotherapeutic response of colorectal liver metastases with dynamic gadolinium-DTPA-enhanced MRI and localized 19F MRS pharmacokinetic studies of 5-fluorouracil. NMR Biomed 2007, 20:128-140.
61. Vriens D., Geus-Oei L., Heerschap A., van Laarhoven H.W., Oyen W.J. Vascular and metabolic response to bevacizumab-containing regimens in two patients with colorectal liver metastases measured by dynamic contrast enhanced MRI and dynamic 18F-FDG PET. Clin Colorectal Cancer 2010, 10:E1-E5.
62. Batchelor T.T., Sorensen A.G., di T.E., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11:83-95.
63. Davis T.W., O'Neal J.M., Pagel M.D., et al. Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature. Cancer Res 2004, 64:279-285.
64. Yankeelov T.E., Lepage M., Chakravarthy A., et al. Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Magn Reson Imaging 2007, 25:1-13.
65. Kamel I.R., Reyes D.K., Liapi E., Bluemke D.A., Geschwind J.F. Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2007, 18:49-56.
66. Manton D.J., Chaturvedi A., Hubbard A., et al. Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy. Br J Cancer 2006, 94:427-435.
67. Leimgruber A., Ostermann S., Yeon E.J., et al. Perfusion and diffusion MRI of glioblastoma progression in a four-year prospective temozolomide clinical trial. Int J Radiat Oncol Biol Phys 2006, 64:869-875.
68. Rijpkema M., Kaanders J.H., Joosten F.B., van der Kogel A.J., Heerschap A. Method for quantitative mapping of dynamic MRI contrast agent uptake in human tumors. J Magn Reson Imaging 2001, 14:457-463.
69. Tofts P.S., Brix G., Buckley D.L., et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999, 10:223-232.
70. van Laarhoven H.W., Rijpkema M., Punt C.J., et al. Method for quantitation of dynamic MRI contrast agent uptake in colorectal liver metastases. J Magn Reson Imaging 2003, 18:315-320.
71. 1H NMR spectroscopic imaging of human prostate cancer. J Magn Reson Imaging 2004, 20:279-287.
72. Wahl R.L., Jacene H., Kasamon Y., Lodge M.A. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009, 50(Suppl 1):122S-150S.
73. Therasse P., Eisenhauer E.A., Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 2006, 42:1031-1039.
74. Eisenhauer E.A., Therasse P., Bogaerts J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.